Prostate Cancer - Results from #440

Early Identification and Management of Patients with Rash on Apalutamide. August 7, 2024

From foes to friends: rethinking the role of lymph nodes in prostate cancer. August 7, 2024

Performance Status and End-of-Life Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer Treated With Androgen Receptor Targeted Therapy. August 7, 2024

18F-DCFPyL PSMA PET/CT Tracheobronchial Uptake in Patients with Prostate Cancer: Incidence and Etiology. August 7, 2024

Utility of 64Cu-Sarcophagine-Bombesin PET/CT in Men with Biochemically Recurrent Prostate Cancer and Negative or Equivocal Findings on 68Ga-PSMA-11 PET/CT. August 7, 2024

Urine biomarkers can predict prostate cancer and PI-RADS score prior to biopsy. August 7, 2024

Impact of Clinical Factors on 18F-Flotufolastat Detection Rates in Men With Recurrent Prostate Cancer: Exploratory Analysis of the Phase 3 SPOTLIGHT Study. August 7, 2024

Artera Announces Expansion of the ArteraAI Prostate Test to Inform Active Surveillance Decisions for Lower Risk Prostate Cancer Patients August 6, 2024

Racial, ethnic, and socioeconomic disparities in rates of stage IV prostate cancer after USPSTF category "D" recommendation against prostate-specific antigen screening: a retrospective cohort study. August 6, 2024

Impact of time to metastatic disease onset and extent of disease volume across metastatic hormone-sensitive and castration-resistant prostate cancer. August 6, 2024

PSA Levels and Mortality in Prostate Cancer Patients. August 6, 2024

Assessing the Heterogeneity of Response of [68Ga] Ga-PSMA-11 PET/CT Lesions in Patients With Biochemical Recurrence of Prostate Cancer. August 6, 2024

Clinical, Imaging, and Technical Factors Associated with Successful Genomic Profiling of Bone Biopsy Tissue in Prostate Cancer. August 6, 2024

Transperineal Versus Transrectal Magnetic Resonance Imaging-targeted Prostate Biopsy: A Systematic Review and Meta-analysis of Prospective Studies. August 6, 2024

Association Between the Decipher Genomic Classifier and Prostate Cancer Outcome in the Real-world Setting. August 6, 2024

De-escalation of Monitoring in Active Surveillance for Prostate Cancer: Results from the GAP3 Consortium. August 5, 2024

Assessments of prostate cancer cell functions highlight differences between a pan-PI3K/mTOR inhibitor, gedatolisib, and single-node inhibitors of the PI3K/AKT/mTOR pathway. August 5, 2024

Salvage treatments after focal therapy for prostate cancer - a comprehensive review. August 5, 2024

Evidence and emerging trends in local therapy for metastatic hormone-sensitive prostate cancer: a narrative review. August 5, 2024

Apalutamide for High-Risk Localized Prostate Cancer Following Radical Prostatectomy (Apa-RP). August 5, 2024

Page 23 of 1435